B r i e f c o m m u n i c at i o n s
IFN-γ is a pro-inflammatory cytokine that acts as a potent activator of microglia and astrocytes 1 . As we examined the effects of various immune-modulatory factors in mouse models of neurodegenerative disease 2, 3 , we noted that overexpression of mouse IFN-γ (mIFN-γ) in wild-type mice resulted in a previously unreported CNS phenotype mimicking human IBGC, a neurodegenerative syndrome distinguished by bilateral calcification of the basal ganglia 4 , and age-progressive nigrostriatal degeneration. All of the animal procedures that we used were approved by the Institutional Animal Care and Use Committee of the Mayo Clinic. In these studies, B6C3 mice pups were injected in the cerebral ventricles with recombinant adeno-associated viruses expressing mIFN-γ (rAAV2/1-mIFN-γ) or enhanced GFP (rAAV2/1-EGFP) on postnatal day 2 (P2; Supplementary Methods). This resulted in transgene expression largely in the choroid plexus and ependymal cells of the ventricle and a limited number of cells in the parenchyma surrounding the ventricles ( Supplementary Fig. 1a-h ) 2 . Mice infected with rAAV2/1-EGFP were used as controls in subsequent experiments, as expression of rAAV2/1-EGFP has no appreciable effect on gliosis or CNS pathology when compared with uninjected or phosphate-buffered saline-injected mice 2, 3 .
rAAV2/1-mIFN-γ expression recapitulated a number of features that were previously observed in Ifng transgenic mice in which the B r i e f c o m m u n i c at i o n s transgene was expressed in the CNS using the oligodendrocytespecific myelin basic promoter 5, 6 . Expression of mIFN-γ in the brain was significantly increased following P2 injection of rAAV2/1-mIFN-γ (P < 0.05), ~50% of the mice died by 5 months of age and we observed runting ( Supplementary Fig. 1i-k) . These mice showed extensive microgliosis and astrocytosis in the CNS, consistent with the induction of the M1 macrophage phenotype (Fig. 1a-d and Supplementary Fig. 2a-h) , indicating that the effect of rAAV2/1-mIFN-γ expression is non-cell autonomous. There was no evidence for T-cell infiltration in these mice ( Supplementary  Fig. 2i−l) . We also observed significant demyelination in the corpus callosum and cerebellar granule cell abnormalities, consistent with a migratory defect (P < 0.05; Supplementary Fig. 2m−v) , similar to previous reports 5, 6 . Expression of rAAV2/1-mIFN-γ resulted in unique pathologies that have not been reported. Brain sections stained with hematoxylin and eosin revealed numerous intensely basophilic lesions in the basal ganglia that we determined to be mineralized calcified deposits (Fig. 1e-h and Supplementary  Fig. 3a−h ). These deposits formed in the thalamus and midbrain and occasionally in the cerebellum, with no deposits being apparent in the cortex. Calcification was evident in both 5-and 8-month-old cohorts and was evident in both B6/C3H and B6/SJL backgrounds. This pathology is reminiscent of human IBGC or striopallidodentate calcification, which is characterized by neurological features such as Parkinsonism 7 , dystonia, tremor and chorea and neuropsychiatric symptoms such as psychosis and cognitive decline 4 . It is clinically and biochemically distinct from disorders of systemic calcium or phosphate metabolism such as parathyroid disease.
Further examination of the mIFN-γ mice and individuals with IBGC revealed spatially similar calcification patterns (Supplementary Fig. 3a-j) and focal activation of microglia and astrocytes (Supplementary Fig. 3k-p) . Electron microscopy ( Fig. 1i-n) showed that calcification in mIFN-γ mice was primarily extracellular, occurring both in the parenchyma and perivascular spaces, but we also observed sparse intracellular calcification, with features previously noted in individuals with IBGC 4 . Swollen axons with accumulation of neurofilaments were also apparent. Using silver impregnation techniques, we found degenerative changes, axonal swelling and intracellular argyrophilic inclusions in the midbrain of mIFN-γ mice (Supplementary Fig. 4 ). This pathology has not been previously described in oligodendrocyte-specific promoter-driven Ifng transgenic mouse models 5, 6 . 
Clinical and pathological data indicate that there is dopaminergic dysfunction in individuals with IBGC 8, 9 . To evaluate whether mIFN-γ resulted in nigrostriatal degeneration in these mice, we examined protein phosphatase 1, regulatory (inhibitor) subunit 1B (DARPP32 or PPP1R1B) and tyrosine hydroxylase expression (Fig. 2) . At 3 months, there was no change in DARPP32 (Fig. 2c-e) or tyrosine hydroxylase (Fig. 2i-k) immunoreactivity between mIFN-γ mice and controls, despite the presence of calcinosis. At 5 months, there was a 50% decrease (P < 0.05) in DARPP32-immunoreactive cell bodies and a 74% decrease (P < 0.001) in DARPP32 protein levels assessed by immunoblotting in the mIFN-γ mice (Fig. 2a,b,e,f and Supplementary  Fig. 5) . Similarly, there was a marked 84% loss (P < 0.001) of tyrosine hydroxylase immunoreactivity at 5 months, consistent with nigrostriatal denervation (Fig. 2g,h,k) . Estimates of remaining cells showed an 84% decrease (P < 0.001) in the number of tyrosine hydroxylaseexpressing cells in the midbrain and pons and a 65% loss (P < 0.001) in the number of tyrosine hydroxylase-expressing cells in the substantia nigra pars compacta (SNc) in mIFN-γ mice (Fig. 2l-n) . In contrast there was no substantial change in the number of pyramidal cells in the hippocampus in mIFN-γ mice (2% decrease; Fig. 2o,p) , indicating that the nigrostriatal neurons are more vulnerable to the effects of mIFN-γ than hippocampal neurons. rAAV2/1-mIFN-γ expression in ex vivo tyrosine hydroxylase-positive mouse primary neuronal or mixed neuroglial striatal cultures resulted in apoptosis and necrosis, as evident by TUNEL assay and increased annexin V immunostaining ( Supplementary Fig. 6a-l) . Although it appears that mIFN-γ expression causes toxicity in both cultured neurons and neuroglial cultures, additional studies will be needed to determine the mechanism underlying the neurotoxicity of mIFN-γ in culture and in vivo.
To test for basal ganglia dysfunction, we performed beam-walking and open field exploratory tests on 8-month-old mIFN-γ and EGFP mice. In the beam-walking test, mIFN-γ mice were immobile for longer periods of time and their walking time to reach the goal was significantly higher than that of control animals (P < 0.05; Fig. 2q ), although the latency to initiate movement was the same in both the groups ( Supplementary  Fig. 7a) . In an open field, mIFN-γ mice were more immobile and spent more time resting (P < 0.05 ; Fig. 2r) ; the path length traversed and latency periods were essentially unchanged (Supplementary Fig. 7b) . Collectively, these features are reminiscent of akinetic symptoms in humans and dopamine-deficient mice 10 . In contextual fear conditioning (Supplementary Fig. 7c) , the mIFN-γ mice showed more freezing than controls, suggestive of Parkinsonian freezing of gait 10 .
Encephalitis or viral infection can cause Parkinsonism 11 . Notably, some sporadic forms of IBGC appear to have infectious etiologies such as intrauterine or perinatal infections associated with toxoplasmosis, rubella, herpesvirus and HIV1 (ref. 4) . To investigate whether neuroinflammation by itself leads to nigrostriatal degeneration, we tested the effect of murine interleukin-6 (mIL-6), a pro-inflammatory cytokine, in wild-type mice. rAAV2/1-mIL-6 expression in the CNS caused widespread gliosis (Supplementary Fig. 8a,b and ref. 2), similar to that observed in the mIFN-γ mice ( Supplementary  Fig. 2a−d) , but did not cause midbrain calcification and did not increase mIFN-γ RNA or protein expression ( Supplementary  Fig. 8c-e) . Notably, in mIL-6 mice, there were no alterations in tyrosine hydroxylase or DARPP32 levels ( Supplementary Fig. 8f-k) . Moreover, injection of rAAV2/1-mIFN-γ into the thigh muscles of wild-type neonatal mice elevated plasma mIFN-γ and resulted in local macrophage activation, muscle dystrophy and calcinosis at 5 months (Supplementary Fig. 9 and ref. 12) . Thus, calcification and neurodegeneration appear to be the direct results of mIFN-γ and not nonspecific consequences of chronic neuroinflammation.
The notable feature of the neurodegeneration seen in rAAV2/1-mIFN-γ mice is its relative selectivity for the basal ganglia and nigrostriatal pathways. High serum levels of IFN-γ and TNFα are associated with IBGC 13 , as well as a number of other neurodegenerative movement disorders, including Parkinson's disease 14 . Notably, Parkinsonism can occur following viral encephalitis 11 , providing a link between post-encephalitic Parkinsonism and the IFN-γ-mediated anti-viral response. Previous studies have shown that IFN-γ-driven microglial activation is required for dopaminergic neurodegeneration induced by paraquat, MPTP and rotenone (reviewed in ref. 15) . Although innate immune mediators such as IFN-γ, TNFα and IL-1β can exacerbate toxin-driven nigrostriatal degeneration 15 , frank nigrostriatal degeneration in the absence of an additional stressor has not been demonstrated. Our results provide compelling in vivo evidence that IFN-γ can directly mediate robust, selective and progressive nigrostriatal degeneration, and antagonism of IFN-γ signaling may hold potential therapeutic benefit for diseases that result in nigrostriatal degeneration and basal ganglia calcification.
Note: Supplementary information is available on the Nature Neuroscience website.
